NU553 Unit 2 Study Guide

Student Name

Purdue University Globle 

NU553 Advanced Pharmacology and Pharmacotherapeutics

Prof. Name

Date

U553 Unit 2: High-Yield Pharmacology and Pain Management Study Guide

Understanding neurotransmitter function, medication mechanisms, patient monitoring, and evidence-based prescribing principles is essential for success in advanced psychiatric and pain management practice. The highest-yield concepts include selecting medications based on neurotransmitter abnormalities, monitoring for adverse effects, individualizing therapy, and combining pharmacologic treatment with psychotherapy, lifestyle interventions, and patient education to achieve the best clinical outcomes.

Why Neurotransmitters Matter in Clinical Practice

Neurotransmitters form the foundation of psychiatric pharmacology because they influence mood, cognition, anxiety, attention, sleep, and behavior. Recognizing neurotransmitter imbalances allows nurse practitioners to select medications that target the underlying pathophysiology while anticipating therapeutic benefits and adverse reactions.

Effective treatment decisions require balancing:

• Medication effectiveness

• Potential adverse effects

• Patient preferences

• Medical comorbidities

• Long-term treatment goals

Medication alone is rarely sufficient. Optimal outcomes are achieved through a combination of pharmacotherapy, psychotherapy, lifestyle modification, and ongoing patient education.

Neurotransmitter Patterns Associated With Major Psychiatric Disorders

Understanding common neurotransmitter abnormalities helps clinicians predict medication response and guide treatment selection.

These neurotransmitter relationships serve as the basis for choosing antidepressants, anxiolytics, antipsychotics, stimulants, and sleep medications.

Antidepressants: High-Yield Clinical Concepts

Selecting First-Line Therapy

Selective serotonin reuptake inhibitors (SSRIs) remain the preferred first-line treatment for most depressive disorders because they provide favorable safety profiles and good tolerability.

Common SSRIs include:

• Sertraline

• Fluoxetine

• Citalopram

• Escitalopram (Lexapro)

Serotonin-norepinephrine reuptake inhibitors (SNRIs), including venlafaxine and duloxetine, increase both serotonin and norepinephrine levels and may be particularly beneficial for patients experiencing fatigue or neuropathic pain.

Medication selection should always consider:

• Presenting symptoms

• Coexisting medical conditions

• Previous medication response

• Adverse-effect profile

Important Medication Pearls

Bupropion is considered an activating antidepressant and may reduce SSRI-associated sexual dysfunction. Mirtazapine commonly causes sedation and may be beneficial for patients with insomnia or reduced appetite.

Monitoring During Treatment

Patients require close monitoring during the first several weeks of therapy because increased energy levels may occur before mood improvement, potentially increasing suicide risk in vulnerable individuals.

Clinicians should monitor for:

• Serotonin syndrome

• Emerging suicidal thoughts

• Medication adherence

• Early adverse effects

Antidepressants should be tapered gradually to reduce withdrawal symptoms.

Mechanisms of Major Antidepressant Classes

Anxiolytics: Choosing the Appropriate Medication

Benzodiazepines

Benzodiazepines enhance GABA activity, producing rapid symptom relief. However, they should primarily be reserved for short-term or situational anxiety because of their potential for dependence and misuse.

Long-term use should generally be avoided, particularly among older adults.

Safety considerations include:

• Risk of tolerance and dependence

• Controlled substance monitoring

• Avoiding abrupt discontinuation

• Avoiding concurrent alcohol or CNS depressants

Buspirone

Buspirone provides a non-benzodiazepine option for generalized anxiety disorder.

Key characteristics include:

• Acts on serotonin receptors

• No significant sedation

• Minimal abuse potential

• Requires several weeks before clinical improvement

Patients experiencing acute panic symptoms typically require faster-acting alternatives.

First-Line Treatment for Chronic Anxiety

SSRIs and SNRIs remain the preferred long-term pharmacologic treatment and should be combined with cognitive behavioral therapy (CBT), relaxation techniques, and lifestyle interventions whenever appropriate.

Antipsychotic Medications: Essential Differences

First-Generation Antipsychotics

Typical antipsychotics primarily block dopamine D2 receptors and effectively reduce positive symptoms of schizophrenia. However, they carry a higher risk of extrapyramidal symptoms (EPS).

Clinicians should monitor for tardive dyskinesia, including:

• Involuntary facial movements

• Finger movements

• Leg movements

Second-Generation Antipsychotics

Atypical antipsychotics affect both dopamine and serotonin receptors, improving negative symptoms while reducing EPS risk compared with first-generation agents.

Monitoring for Metabolic Complications

Routine monitoring should include:

• Comprehensive metabolic panel (CMP)

• Lipid profile

• Weight

• Vital signs

• Medication adherence

Clozapine Monitoring

Clozapine requires routine white blood cell monitoring because of the risk of agranulocytosis.

Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) is a rare but life-threatening emergency associated with antipsychotic therapy.

Risk factors include:

• High-potency antipsychotics

• Rapid dose escalation

• Dehydration

• Previous NMS

• Organic brain disease

Mood Stabilizers

Lithium

Lithium remains the gold standard for bipolar disorder management.

The therapeutic serum concentration typically ranges between 0.6 and 1.2 mEq/L, requiring regular monitoring because of its narrow therapeutic index.

Patients require routine evaluation of:

• Lithium serum levels

• Kidney function

• Thyroid function

Patient education should emphasize:

• Maintaining hydration

• Consistent sodium intake

• Avoiding NSAIDs when possible

• Recognizing toxicity symptoms such as tremor and confusion

Anticonvulsants

Alternative mood stabilizers include:

• Valproic acid

• Lamotrigine

• Carbamazepine

Monitoring focuses on hepatic toxicity and serious dermatologic reactions.

ADHD Medications

Attention-deficit/hyperactivity disorder (ADHD) medications improve concentration and impulse control by increasing dopamine and norepinephrine activity within the prefrontal cortex.

Stimulants

First-line medications include:

• Methylphenidate

• Amphetamine preparations

Non-Stimulants

Alternative options include atomoxetine and other non-stimulant agents, particularly for individuals with cardiovascular concerns or increased substance misuse risk.

Clinical Monitoring

Regular assessment should include:

• Blood pressure

• Heart rate

• Appetite

• Weight

• Sleep quality

Cardiac history should be evaluated before initiating stimulant therapy.

Pharmacologic Management of Sleep Disorders

Non-Drug Therapy Comes First

Initial management should prioritize behavioral interventions, including:

• Consistent sleep schedules

• Sleep hygiene

• Relaxation techniques

• Mindfulness

• Cognitive behavioral therapy for insomnia

Medication Options

Common pharmacologic therapies include:

• Zolpidem

• Ramelteon

• Trazodone

• Low-dose doxepin

Clinicians should prescribe the lowest effective dose while monitoring for:

• Next-day sedation

• Cognitive impairment

• Complex sleep behaviors such as sleepwalking

Special Considerations for Vulnerable Populations

Medication therapy should always be individualized based on patient characteristics.

Older Adults

Older adults are more susceptible to:

• CNS depression

• Anticholinergic adverse effects

• Falls

Treatment should follow the “start low and go slow” principle.

Pregnancy

Medication selection requires careful evaluation of fetal safety. Valproate should generally be avoided because of teratogenic risk, while SSRIs require individualized risk-benefit assessment.

Adolescents

Young patients beginning antidepressants require close observation for worsening depression and suicidal ideation.

Patients With Substance Use Disorders

Whenever feasible, clinicians should avoid medications with significant abuse potential and instead consider non-addictive alternatives.

Ethical and Legal Responsibilities for Prescribers

Advanced practice providers are responsible for delivering evidence-based, patient-centered care while maintaining legal and ethical standards.

Best practices include:

• Shared decision-making

• Informed consent

• Thorough documentation

• Appropriate controlled-substance agreements

• Prescription Drug Monitoring Program (PDMP) review

• Monitoring for misuse and diversion

• Collaboration with psychiatry, primary care, and behavioral health professionals

Clinical Monitoring Throughout Treatment

Baseline laboratory testing may include:

• Complete blood count (CBC)

• Electrolytes

• Liver function tests

• Renal function

• Blood glucose

• Lipid profile

Follow-up visits should evaluate:

• Symptom improvement

• Medication adherence

• Adverse effects

• Treatment response

Validated assessment tools such as the PHQ-9 and GAD-7 should be repeated approximately 6 to 8 weeks after treatment initiation to monitor progress.

Patients should promptly report symptoms including:

• Restlessness

• Muscle rigidity

• Suicidal thoughts

• Severe sedation

Pain Management Principles

Effective pain management begins with identifying the underlying pain mechanism and selecting treatments that address the specific cause while minimizing adverse effects.

Medication selection should consider:

• Pain type

• Severity

• Comorbidities

• Risk of medication dependence

Types of Pain

Neuropathic pain often responds better to adjuvant medications such as gabapentinoids and SNRIs than to opioids alone.

Mechanism-Based Pain Management

Treatment should target the underlying pain mechanism.

Non-Pharmacologic Pain Management

Multimodal therapy improves long-term outcomes by combining medication with supportive interventions.

Evidence-based non-pharmacologic approaches include:

• Heat and cold therapy

• Massage

• Therapeutic Neuroscience Education (TNE)

• Cognitive behavioral therapy

• Transcutaneous electrical nerve stimulation (TENS)

• Acupuncture

• Mindfulness and meditation

These therapies complement—not replace—appropriate pharmacologic treatment.

Co-Analgesic Medications

Adjunctive medications enhance pain relief while reducing opioid exposure.

Common options include:

• Duloxetine

• Venlafaxine

• Amitriptyline

• Gabapentin

• Pregabalin

• Lidocaine patches

• Ketamine (selected refractory cases)

• Cyclobenzaprine

• Baclofen

• Tizanidine

Interventional Options for Chronic Pain

For pain lasting longer than three to six months, procedural interventions may be appropriate.

Examples include:

• Steroid injections

• Nerve blocks

• Trigger-point injections

• Radiofrequency rhizotomy

• Neuromodulation

• Vertebroplasty

• Kyphoplasty

• Selected spinal procedures

Opioid Use Disorder and Safe Pain Management

Pain management should prioritize reducing misuse while maintaining adequate symptom control.

Recommended strategies include:

• Using non-opioid therapies first

• Prescribing the lowest effective opioid dose only when necessary

• Combining pharmacologic and non-pharmacologic therapies

• Coordinating care with addiction specialists

• Educating patients regarding opioid risks

Assessment should include:

• Functional status

• Comprehensive pain history

• Screening for opioid misuse

• PDMP review

• Opioid Risk Tool (ORT) when appropriate

Patients with opioid use disorder should have current treatment regimens verified before initiating additional opioid therapy.

Treatment goals include:

• Pain relief

• Improved function

• Reduced cravings

• Prevention of relapse

• Improved quality of life

Common medications discussed include naloxone, methadone, and partial opioid agonists used in medication-assisted treatment.

Key Clinical Takeaways

• Neurotransmitter abnormalities guide medication selection across psychiatric disorders.

• SSRIs remain first-line therapy for depression and chronic anxiety because of favorable safety and efficacy.

• Lithium requires regular monitoring of serum levels, kidney function, and thyroid function.

• Antipsychotics require metabolic monitoring, while clozapine additionally requires routine white blood cell monitoring.

• ADHD stimulants require cardiovascular assessment and ongoing monitoring of appetite, weight, sleep, and blood pressure.

• Non-pharmacologic interventions should always be considered first-line for insomnia and should complement medication therapy for chronic pain.

• Safe opioid prescribing emphasizes comprehensive assessment, multimodal treatment, risk mitigation, and ongoing monitoring.

Frequently Asked Questions

What neurotransmitters are most commonly involved in depression?

Depression is primarily associated with dysregulation of serotonin and norepinephrine, although dopamine dysfunction may also contribute in some patients. These neurotransmitter abnormalities guide the use of antidepressant medications such as SSRIs and SNRIs.

Why are SSRIs considered first-line treatment for depression?

SSRIs are generally preferred because they effectively improve depressive symptoms while offering a favorable safety profile, fewer serious adverse effects than older antidepressants, and good long-term tolerability.

What laboratory monitoring is required for lithium therapy?

Patients receiving lithium require regular monitoring of serum lithium concentrations, kidney function, thyroid function, and clinical signs of toxicity because lithium has a narrow therapeutic range.

What should clinicians monitor when prescribing antipsychotic medications?

Routine monitoring includes weight, blood pressure, lipid profile, glucose, metabolic laboratory tests, medication adherence, and extrapyramidal symptoms. Clozapine additionally requires ongoing white blood cell monitoring.

What is the preferred initial treatment for chronic anxiety disorders?

Current clinical guidelines recommend SSRIs or SNRIs combined with psychotherapy, particularly cognitive behavioral therapy, as first-line treatment for most chronic anxiety disorders.

How should chronic pain be managed safely?

Chronic pain is best managed using a multimodal approach that combines appropriate medications, physical therapies, behavioral interventions, patient education, and careful monitoring while minimizing opioid exposure whenever possible.

Effective psychiatric and pain management depends on understanding neurotransmitter physiology, selecting medications based on evidence, monitoring patients closely, and integrating pharmacologic therapy with behavioral and lifestyle interventions. Individualized, patient-centered care improves treatment outcomes while reducing medication-related complications.

References

American Psychiatric Association. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841

Bandelow, B., Michaelis, S., & Wedekind, D. (2022). Treatment of anxiety disorders. Dialogues in Clinical Neuroscience, 24(1), 1–15. https://www.tandfonline.com/doi/full/10.1080/19585969.2022.2042160

NU553 Unit 2 Study Guide

National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222). https://www.nice.org.uk/guidance/ng222

National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms. https://www.nice.org.uk/guidance/ng215

Substance Abuse and Mental Health Services Administration. (2024). TIP 63: Medications for opioid use disorder. https://store.samhsa.gov/product/tip-63-medications-for-opioid-use-disorder

Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press. https://www.cambridge.org/core/books/stahls-essential-psychopharmacology/